Canadian Health Coalition
  • Donate

    The form is not published.

  • Menu Canvas
    • CHC Home
    • News
    • About us
    • Campaigns
    • Take action
    • Contact
    • Donate
  • hello@healthcoalition.ca
  • 343-558-1788
Donate | Subscribe
    • English
Canadian Health Coalition
  • Home
  • About us
    • Our Team
  • News
  • Campaigns
  • Take action
  • Ways to Give
    • Give one-time
    • Become a monthly donor
    • Leave a gift in your will
    • Make a tribute donation
  • Contact
  • Donate

The free market is no solution to sky-high drug prices

Homepage Commentary The free market is no solution to sky-high drug prices
Commentary

The free market is no solution to sky-high drug prices

August 2, 2022
By Steven Staples
0 Comment
913 Views

An expert on pharmaceuticals says a recent article by a conservative think tank relies on myths and focuses on the wrong data when it argues against government rules to lower rampant drug costs. 

Dr. Joel Lexchin is an emergency room physician, an associate professor with the University of Toronto’s Institute of Health Policy, Management and Evaluation, and sits on the board of the Canadian Health Coalition.

Below is Dr. Lexchin’s response to a July 4, 2022 article published in the influential The Hill Times by Brent Skinner, CEO of the Canadian Health Policy Institute. The response to Skinner’s article was published in The Hill Times on July 27, 2022.


Remove ideology from drug-price debate, writes health coalition board member

Re: “Is drug price policy evidence-based or evidence-deficient?” (The Hill Times, July 4).

Brett Skinner’s recent opinion piece is a rehash of arguments that he and other free market advocates have been making about the changes to the Patented Medicine Prices Review Board (PMPRB) regulations ever since they were first muted back in 2016. Skinner makes much of the two court rulings that went against the federal government and caused it to withdraw two of the three proposed changes. But the government chose not to appeal those decisions to a higher court. Was this decision by the government because it got legal advice that it was unlikely to be successful or was it due to pressure and lobbying from the pharmaceutical industry?

Skinner believes that since the cost of patented drugs have never exceeded eight per cent of national health expenditures that drug costs are not a problem. But is eight per cent the most important number that we should be concerned about? What about the 23 per cent who told the 2020 Angus Reid poll that in the previous year they had tried to make a prescription last longer by splitting doses or not filling a prescription because of cost?

Skinner notes that the provinces negotiate secret discounts on the price of patent medicines to the tune of as much as 36 per cent. But those discounts are not available to the most vulnerable segment of the population: the working poor. They pay the full list price. More than 35 per cent of low-income Canadians without drug insurance report cost-related non-adherence.

What about the $82-million annually that funds the various Canadian agencies that deal with prices and determine cost effectiveness? Skinner says that instead we could spend that money to improve access to a group of undefined “underfunded therapies.” In terms of the $14.7-billion in public spending on drugs in 2019, $82-million is a drop in the bucket.

Skinner continues to repeat the myth that low drug prices will deprive Canadians of innovative medicines, implying that without these medicines, our health will suffer. The notion that companies will delay the introduction of new drugs into Canada because of lower prices or not introduce them at all comes from a survey of pharmaceutical company executives done by Life Sciences Ontario, an organization with a membership including multiple pharmaceutical companies. The results of that survey have not been independently validated.

As an elderly man, I take drugs for some conditions, and as an emergency department doctor, I prescribe drugs, so I know their value from both sides. But the reality is that only a small minority of new drugs offer a major therapeutic gain over existing products. The reason that many of the rest exist is to make money for the companies marketing them.

It’s time to get ideology out of this debate and focus on what really matters, the amount of money that Canadians, especially poor and marginalized ones, are paying for the drugs that they need to keep themselves healthy.

Dr. Joel Lexchin is a Canadian Health Coalition board member and a professor emeritus at the School of Health Policy and Management, Faculty of Health, York University.
The Hill Times, July 27, 2022

Tags: Pharmacare

Previous Story
Paid plasma industry is threatening Canada’s blood supply: panel
Next Story
Ford government encouraged to permanently fund health care for migrants

Related Articles

Carney to announce new health minister next week

The first of major announcements affecting public health care

Pharmacare must expand as Trump’s tariffs threaten prescription drug access in Canada

Now is the time for full national coverage

Recent Posts

  • Without mental health and substance use care, Canada’s health care system is not universal May 12, 2025
  • Carney to announce new health minister next week May 7, 2025
  • Pharmacare must expand as Trump’s tariffs threaten prescription drug access in Canada May 7, 2025
  • Research roundtable to examine Canada’s health care profitization problem May 6, 2025
  • Carney’s new government must deliver on public health care Apr 30, 2025

Tags

Canada Health Act Canada Health Transfer Canadian Health Coalition COVID-19 Dental Care Federal Election 44 Federal Election 45 Health+Hope 2025 Health Care Workers Health Policy Home care Long-term Care Medicare Mental Health Pharmacare Plasma Privatization Racism Reproductive Health Care Sexual and reproductive health and rights Solutions series Substance use care Toxic drug crisis
Canadian Health Coalition
2841 Riverside Dr.
Ottawa, Ontario K1V 8X7
+343.558.1788
hello@healthcoalition.ca
  • Home
  • What we do
  • Campaigns
  • News
  • Contact
SearchPostsLogin
Monday, 12, May
Without mental health and substance use care, Canada’s health care system is not universal
Wednesday, 7, May
Carney to announce new health minister next week
Wednesday, 7, May
Pharmacare must expand as Trump’s tariffs threaten prescription drug access in Canada
Tuesday, 6, May
Research roundtable to examine Canada’s health care profitization problem
Wednesday, 30, Apr
Carney’s new government must deliver on public health care
Wednesday, 30, Apr
Senior care deserves priority action in the aftermath of the election

Welcome back,